Aurobindo Phama has launched its line of Oral Contraceptive tablets Mili™ and Tri-Mili™
Published: May 11, 2018
East Windsor, N.J. – Aurobindo Pharma Limited is set to launch Mili™ and Tri-Mili™ lines of oral contraceptive tablets June 2018. Aurobindo’s Mili™ and Tri-Mili™ are an AB-rated generic equivalent to the reference listed drugs Ortho Cyclen® and Ortho Tri-Cyclen®. Please see below table for specific product information.
|
Product Name |
Strength |
Brand Equivalent |
| Mili™ Norgestimate and Ethinyl Estradiol Tablets USP | 0.250 mg / 0.035 mg | Ortho Cyclen® |
| Tri-Mili™ Norgestimate and Ethinyl Estradiol Tablets USP | 0.180 mg / 0.035 mg
0.215 mg / 0.035 mg 0.250 mg / 0.035 mg |
Ortho Tri-Cyclen® |
Mili™ is an estrogen/progestin COC, indicated for use by women to prevent pregnancy. Tri-Mili™ is an estrogen/progestin COC, indicated for use by women to prevent pregnancy and is also indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche.
The combined products have an estimated market size of $389.7M for the twelve months ending February 2018 according to IQVIA*.Mili™ and Tri-Mili ™ line of OC tablets represents the latest addition to Aurobindo’s broad line of generic pharmaceuticals.
* IQVIA National Sales Perspectives: Retail and Non-Retail MAT February 2018
